| Literature DB >> 30424813 |
Min-Chun Chuang1,2, Chih-Hao Chang3,4,5, Chung Shu Lee3,4,5, Shih-Hong Li3,5, Ching-Chung Hsiao5,6, Yueh-Fu Fang3,4,5, Meng-Jer Hsieh7,8.
Abstract
BACKGROUND: Acute cholinesterase inhibitor (CI) poisoning, including organophosphate and carbamate poisoning, is a crucial problem in developing countries. Acute intoxication results in a cholinergic crisis, neurological symptoms, or respiratory failure. However, the short-term and long-term outcomes of CI poisoning are seldom reported.Entities:
Keywords: Intensive care unit; Mechanical ventilation; Organophosphates intoxication; Respiratory failure
Mesh:
Substances:
Year: 2018 PMID: 30424813 PMCID: PMC6234557 DOI: 10.1186/s40360-018-0263-9
Source DB: PubMed Journal: BMC Pharmacol Toxicol ISSN: 2050-6511 Impact factor: 2.483
Characteristics of patients with acute cholinesterase inhibitor poisoning (N = 6832)
| Characteristics | |
|---|---|
| Age, mean ± SD, years old | 55.39 ± 16.44 |
| Female Sex, N (%) | 2038 (29.8) |
| Comorbidities | |
| Diabetes mellitus, N (%) | 773 (11.3) |
| Hypertension, N (%) | 909 (13.3) |
| Coronary artery disease, N (%) | 192 (2.8) |
| Cerebrovascular accident, N (%) | 177 (2.6) |
| Chronic renal failure, N (%) | 53 (0.8) |
| Chronic obstructive pulmonary disease, N (%) | 111 (1.6) |
| Asthma, N (%) | 45 (0.7) |
| Liver failure, N (%) | 30 (0.4) |
| Interventions | |
| Atropine use, N (%) | 3653 (53.5) |
| Pralidoxime use, N (%) | 3479 (50.9) |
| Hemodialysis, N (%) | 124 (1.8) |
| Mechanical ventilation, N (%) | 2010 (29.4) |
| Pneumonia, N (%) | 492 (7.2) |
| Hospital mortality, N (%) | 900 (13.2) |
| Hospital days, mean ± SD | 9.21 ± 11.60 |
Data are presented as mean ± SD or N (%)
Comparison of clinical characteristics between survivors and non-survivors of cholinesterase inhibitor poisoning (N = 6832)
| Non-survivors ( | Survivors ( | 95% CI of difference between means or percentages | ||
|---|---|---|---|---|
| Age, mean ± SD, years old | 62.18 ± 15.48 | 54.36 ± 16.34 | 6.682 to 8.959 | < 0.0001 |
| Female Sex, N (%) | 306 (34.0) | 1732 (29.2) | 1.49 to 8.2% | 0.0033 |
| Comorbidities | ||||
| Diabetes mellitus, N (%) | 117(13.0) | 656 (11.1) | −0.38 to 4.4% | 0.0867 |
| Hypertension, N (%) | 78 (8.7) | 831 (14.0) | 3.09 to 7.28% | < 0.0001 |
| Coronary artery disease, N (%) | 17 (1.9) | 175 (3.0) | −0.097 to 2.02% | 0.0727 |
| Cerebrovascular accident, N (%) | 32 (3.6) | 145 (2.4) | 0.0045 to 2.68% | 0.0506 |
| Chronic renal failure, N (%) | 20 (2.2) | 33 (0.6) | 0.71 to 2.8% | < 0.0001 |
| Chronic obstructive pulmonary disease, N (%) | 16 (1.8) | 95 (1.6) | −0.64 to 1.34% | 0.6967 |
| Asthma, N (%) | 3 (0.3) | 42 (0.7) | −0.25 to 0.75% | 0.195 |
| Liver failure, N (%) | 11 (1.2) | 19 (0.3) | 0.27 to 1.86% | < 0.0001 |
| Atropine use, N (%) | 698 (77.6) | 2955 (49.8) | 0.55 to 4.69% | < 0.0001 |
| Pralidoxime use, N (%) | 564 (62.7) | 2915 (49.1) | 10.1 to 17.02% | < 0.0001 |
| Hemodialysis, N (%) | 59 (6.6) | 65 (1.1) | 3.94 to 7.34% | < 0.0001 |
| Mechanical ventilation, N (%) | 671 (74.6) | 1339 (22.6) | 48.83 to 55.01% | < 0.0001 |
| Pneumonia, N (%) | 85 (9.4) | 407 (6.9) | 0.55 to 4.69% | 0.0052 |
| Hospital days, mean ± SD | 6.58 ± 12.31 | 9.61 ± 11.43 | −3.846 to −2.225 | < 0.0001 |
CI, Confidence interval; Data are presented as mean ± SD or N (%)
Comparison of the clinical characteristics in patients with or without mechanical ventilation (N = 6832)
| With mechanical ventilation | Without mechanical ventilation | 95% CI of difference between means or percentages | ||
|---|---|---|---|---|
| Age, mean ± SD, years old | 58.37 ± 16.38 | 54.15 ± 16.31 | 3.376 to 5.076 | < 0.0001 |
| Female sex, N (%) | 654 (32.5) | 1384 (28.7) | 1.38 to 6.25% | 0.0016 |
| Diabetes mellitus, N (%) | 259 (12.9) | 514 (10.7) | 0.5 to 3.97% | 0.0081 |
| Hypertension, N (%) | 205 (10.2) | 704 (14.6) | 2.68 to 6.05% | < 0.0001 |
| Coronary artery disease, N (%) | 59 (2.9) | 133 (2.8) | −0.75 to 1.04% | 0.6865 |
| Cerebrovascular accident, N (%) | 76 (3.8) | 101 (2.1) | 0.79 to 2.71% | 0.0001 |
| Chronic renal failure, N (%) | 24 (1.2) | 29 (0.6) | 0.098 to 1.21% | 0.0110 |
| Chronic obstructive pulmonary disease, N (%) | 29 (1.4) | 82 (1.7) | −0.41 to 0.92% | 0.4426 |
| Asthma, N (%) | 13 (0.6) | 32 (0.7) | −0.39 to 0.5% | 0.937 |
| Liver failure, N (%) | 13 (0.6) | 17 (0.4) | −0.16 to 0.67% | 0.094 |
| Atropine use, N (%) | 1577 (78.5) | 2076 (43.1) | 33.06 to 37.67% | < 0.0001 |
| Pralidoxime use N (%) | 1453 (72.3) | 2026 (42.0) | 27.84 to 32.7% | < 0.0001 |
| Hemodialysis, N (%) | 83 (4.1) | 41 (0.9) | 2.32 to 4.19% | < 0.0001 |
| Pneumonia, N (%) | 322 (16) | 170 (3.5) | 10.83 to 14.25% | < 0.0001 |
| Hospital mortality rate, N (%) | 671 (33.4) | 229 (4.7) | 26.54 to 30.89% | < 0.0001 |
| Hospital days, mean ± SD | 15.42 ± 16.33 | 6.62 ± 7.54 | 8.224 to 9.358 | < 0.0001 |
CI, Confidence interval; Data are presented as mean ± SD or N (%)
Clinical variables associated with hospital mortality in patients with organophosphate and carbamate poisoning analyzed by multivariate Cox regression (N = 6832)
| Parameter | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age | 1.022 (1.018–1.026) | < 0.0001 | 1.020 (1.015–1.024) | < 0.0001 |
| Female Sex | 1.148 (0.999–1.318) | 0.0506 | ||
| Diabetes | 1.076 (0.885–1.306) | 0.4635 | ||
| Hypertension | 0.629 (0.497–0.794) | < 0.0001 | 0.615 (0.485–0.779) | 0.0001 |
| Coronary artery disease | 0.582 (0.360–0.941) | 0.0273 | 0.485 (0.300–0.785) | 0.0751 |
| Cerebrovascular accident | 1.179 (0.828–1.679) | 0.3607 | ||
| Chronic renal failure | 2.634 (1.690–4.105) | < 0.0001 | 1.449 (0.893–2.351) | 0.1330 |
| Chronic obstructive pulmonary disease | 0.875 (0.534–1.436) | 0.5980 | ||
| Asthma | 0.544 (0.175–1.688) | 0.2920 | ||
| Liver failure | 2.693 (1.486–4.882) | 0.0011 | 2.348 (1.293–4.264) | 0.0050 |
| Atropine | 2.406 (2.054–2.818) | < 0.0001 | 1.951 (1.628–2.337) | < 0.0001 |
| Pralidoxime | 1.184 (1.032–1.359) | 0.0161 | 0.591 (0.506–0.691) | < 0.0001 |
| Hemodialysis | 2.520 (1.929–3.291) | < 0.0001 | 1.454 (1.087–1.946) | 0.0117 |
| Pneumonia | 0.754 (0.600–0.947) | 0.0154 | 0.480 (0.382–0.603) | < 0.0001 |
| Mechanical ventilation | 5.160 (4.426–6.014) | < 0.0001 | 4.684 (3.976–5.517) | < 0.0001 |
CI, Confidence interval; Data are presented as mean ± SD or N (%)
Clinical variables associated with one-year mortality in patients with organophosphate and carbamate poisoning analyzed by multivariate Cox regression (N = 5932)
| Parameter | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age | 1.019 (1.013–1.026) | < 0.0001 | 1.016 (1.009–1.022) | < 0.0001 |
| Female Sex | 0.844 (0.674–1.056) | 0.1385 | ||
| Diabetes mellitus | 1.335 (1.006–1.771) | 0.0451 | 1.185 (0.891–1.575) | 0.2437 |
| Hypertension | 0.962 (0.722–1.282) | 0.7923 | ||
| Coronary artery disease | 1.110 (0.639–1.930) | 0.7110 | ||
| Cerebrovascular accident | 1.026 (0.548–1.923) | 0.9360 | ||
| Chronic renal failure | 1.932 (0.722–5.174) | 0.1900 | ||
| Chronic obstructive pulmonary disease | 1.293 (0.642–2.604) | 0.4722 | ||
| Asthma | 1.071 (0.344–3.337) | 0.9062 | ||
| Liver failure | 0.796 (0.112–5.658) | 0.8194 | ||
| Atropine | 0.992 (0.814–1.207) | 0.9321 | ||
| Pralidoxime | 1.367 (1.121–1.668) | 0.0020 | 1.102 (0.892–1.362) | 0.3669 |
| Hemodialysis | 2.443 (1.304–4.576) | 0.0053 | 1.678 (0.890–3.163) | 0.1095 |
| Pneumonia | 2.860 (2.196–3.725) | < 0.0001 | 1.962 (1.477–2.605) | < 0.0001 |
| Mechanical ventilation | 2.199 (1.796–2.692) | < 0.0001 | 1.722 (1.371–2.162) | < 0.0001 |
CI, Confidence interval; Data are presented as mean ± SD or N (%)
Fig. 1Kaplan-Meier survival curve for the patients with mechanical ventilation and without mechanical ventilation during hospitalization (N = 6832, Logrank test P < 0.0001)
Fig. 2Kaplan-Meier survival curve of the survivors after organophosphate and carbamate poisoning, one year follow up (N = 5932, logrank test, P < 0.0001)